Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?

BACKGROUND: Two strategies for prevention of upper gastrointestinal (UGI) events for non-selective (ns)NSAID users are replacement of the nsNSAID by a cyclo-oxygenase-2-selective inhibitor (coxib) or co-prescription of a gastroprotective agent (GPA). AIM: To identify whether and in whom either of th...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Masclee, Gwen MC, Valkhoff, Vera E, van Soest, Eva M, Schade, René, Mazzaglia, Giampiero, Molokhia, Mariam, Trifirò, Gianluca, Goldstein, Jay L, Hernández-Díaz, Sonia, Kuipers, Ernst J, Sturkenboom, Miriam C J M
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3687334/
https://ncbi.nlm.nih.gov/pubmed/23710837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.12348
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg